US gastroenterologists views on ulcerative colitis drugs

10 July 2017

Results from a recent study just released by Spherix Global Insights reveal that US gastroenterologists (n=103) project significant growth of Takeda Pharmaceutical’s (TYO: 4502) Entyvio (vedolizumab), Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Simponi (golimumab), and Pfizer (NYSE: PFE)/Hospira's infliximab biosimilar, Inflectra, over the next six months.

Infliximab is the active ingredient of J&J’s top-selling drug Remicade, with 2016 sales totaling $7 billion.

While the positive bumps to Entyvio and Simponi's share will be mostly driven by increased prescriptions by current users, Inflectra's projected growth is primarily driven by increases to the user base, which is anticipated to more than double over the next six months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK